Blood Reviews
Volume 21, Issue 3 , Pages 157-171 , May 2007

Circulating microparticles: pathophysiology and clinical implications

  • Andrea Piccin

      Affiliations

    • Irish Blood Transfusion Service, James’s Street, Dublin 8, Ireland
    • Corresponding Author InformationCorresponding author. Tel.: +353 01 4322812.
    • ,
  • William G. Murphy

      Affiliations

    • Irish Blood Transfusion Service, James’s Street, Dublin 8, Ireland
    • ,
  • Owen P. Smith

      Affiliations

    • Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland

References 

  1. Chargaff E, West R. The biological significance of the thromboplastic protein of blood. J Biol Chem. 1946;166:189–197
  2. Wolf P. The nature and significance of platelet products in human plasma. Brit J Haematol. 1967;13(3):269–288
  3. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104(1):93–102
  4. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol. 1994;153(7):3245–3255
  5. Iida K, Whitlow MB, Nussenzweig V. Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol. 1991;147:2638–2642
  6. Salzer U, Hinterdorfer P, Hunger U, Borken C, Prohaska R. Ca++-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VII), and sorcin. Blood. 2002;99:2569–2577
  7. Wagner GM, Chiu DT, Yee MC, Lubin BH. Red cell vesiculation-a common membrane physiologic event. J Lab Clin Med. 1986;108(4):315–324
  8. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion. 2006;46(1):143–152
  9. Allan D, Thomas P, Limbrick AR. The isolation and characterization of 60nm vesicles (‘nanovesicles’) produced during ionophore A23187-induced budding of human erythrocytes. Biochem J. 1980;188(3):881–887
  10. Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122(2):429–436
  11. Zwaal RF, Bevers EM. Platelet phospholipid asymmetry and its significance in hemostasis. Subcell Biochem. 1983;9:299–334
  12. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256(7):3433–3442
  13. Rosing J, Speijer H, Zwaal RF. Prothrombin activation on phospholipid membranes with positive electrostatic potential. Biochemistry. 1988;27(1):8–11
  14. Schroit AJ, Tanaka Y, Madsen J, Fidler IJ. The recognition of red blood cells by macrophages: role of phosphatidylserine and possible implications of membrane phospholipid asymmetry. Biol Cell. 1984;51(2):227–238
  15. Fox JE, Austin CD, Boyles JK, Steffen PK. Role of the membrane skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol. 1990;111(2):483–493
  16. Diaz C, Schroit AJ. Role of translocases in the generation of phosphatidylserine asymmetry. J Membr Biol. 1996;151(1):1–9
  17. Connor J, Pak CH, Zwaal RF, Schroit AJ. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells Evidence for an ATP-dependent and protein-mediated process. J Biol Chem. 1992;267(27):19412–19417
  18. McLaughlin PJ, Gooch JT, Mannherz HG, Weeds AG. Structure of gelsolin segment 1-actin complex and the mechanism of filament severing. Nature. 1993;364(6439):685–692
  19. Beleznay Z, Zachowski A, Devaux PF, Navazo MP, Ott P. ATP-dependent aminophospholipid translocation in erythrocyte vesicles: stoichiometry of transport. Biochemistry. 1993;32(12):3146–3152
  20. Zwaal RF, Comfurius P, Bevers EM. Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem Soc Trans. 1993;21(2):248–253
  21. Weiss HJ, Vicic WJ, Lages BA, Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med. 1979;67(2):206–213
  22. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta. 2004;1636(2–3):119–128
  23. Dachary-Prigent J, Pasquet JM, Fressinaud E, Toti F, Freyssinet JM, Nurden AT. Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics. Brit J Haematol. 1997;99(4):959–967
  24. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 1996;87(4):1409–1415
  25. Castaman G, Yu-Feng L, Battistin E, Rodeghiero F. Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation. Brit J Haematol. 1997;96(3):458–463
  26. Murphy WG, Moore JC, Kelton JG. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. Blood. 1987;70:1683–1687
  27. Kelton JG, Warkentin TE, Hayward CP, Murphy WG, Moore JC. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood. 1992;80(9):2246–2251
  28. Harwig JH. Platelet structure. In:  Michelson AD editors. Platelet. Academic Press; 2002;p. 37–49
  29. JY W, Horstman LL, Jimenez JJ, Ahn YS. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2(10):1850–1851
  30. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem. 2002;48:891–899
  31. Philippe J, De Logi E, Baele G. Comparison of five different citrated tubes and their in vitro effects on platelet activation. Clin Chem. 2004;50(3):656–658
  32. Golansky J, Pietrucha T, Baj Z, Greger J, Watala C. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood- various anticoagulant are not equal. Thromb Res. 1996;83:199–216
  33. Biro E, Nieuwland R, Sturk A. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2(10):1843–1844
  34. Shet AS, Key NS, Hebbel RP. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2(10):1848–1850
  35. Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Brit J Haematol. 2004;125(6):804–813
  36. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102(7):2678–2683
  37. Ahmad S, Amirkhosravi A, Langer F, Desai H, Amaya M, Francis JL. Importance of pre-analytical variables in the measurement of platelet-derived microparticles. J Thromb Haemostas. 2005;3(Suppl 1):abstract #02286
  38. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 1991;266(36):24302–24307
  39. Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med. 2004;53(4):210–230
  40. Niuwland R, Strurk A. Platelet derived microparticles. In:  Michelson AD editors. Platelet. Academic Press; 2002;p. 255–265
  41. Nomura S. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004;2(10):1847–1848
  42. Miyamoto S, Marcinkiewicz C, Edmunds LH, Niewiarowski S. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GpIIb/IIIa. Thromb Haemost. 1998;80(2):225–230
  43. Losy J, Niezgoda A, Wender M. Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions. J Neuroimmunol. 1999;99(2):169–172
  44. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, et al. Reversibility versus persistence of GpIIb/IIIa blocker-induced conformational change of GpIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004;308(3):1002–1011
  45. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78(2):340–348
  46. Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P, et al. Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry. 1990;11(5):652–656
  47. von Ahsen N, Ehrlich B, Scott CS, Riggert J, Oellerich M. Cryoglobulins interfere with platelet counts by optical and impedance methods but not with the CD61 immunoplatelet count. Clin Chem. 2001;47(10):1858–1860
  48. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30(2):111–142
  49. Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens. 1997;50(5):449–458
  50. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 2004;9:1118–1135
  51. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109(4):175–180
  52. Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FP, Nieuwland R, Sturk A. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost. 2003;1(11):2434–2443
  53. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85(4):639–646
  54. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264(29):17049–17057
  55. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265(7):3809–3814
  56. Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. Thromb Haemost. 2005;3(6):1301–1308
  57. Celi A, Lorenzet R, Furie BC, Furie B. Microparticles and a P-selectin-mediated pathway of blood coagulation. Dis Markers. 2004;20(6):347–352
  58. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604–1611
  59. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96(1):170–175
  60. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119(4):334–345
  61. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988;263(34):18205–18212
  62. Comfurius P, Bevers EM, Galli M, Zwaal RF. Regulation of phospholipid asymmetry and induction of antiphospholipid antibodies. Lupus. 1995;4(Suppl 1):S19–S22
  63. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci. 1996;93(4):1624–1629
  64. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997;89(7):2429–2442
  65. Francis RB, Hebbel RP. Hemostasis. In:  Embury SH,  Hebbel RP,  Steiberh MH,  Mohandas N editor. Sickle Cell Disease: Basic principles and Clinical practice. New York: Raven Press; 1994;p. 299–310
  66. Manodori AB, Matsui NM, Chen JY, Embury SH. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood. 1998;92(9):3445–3454
  67. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101(9):1899–1904
  68. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91(11):4216–4223
  69. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129–151
  70. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81–88
  71. McKenzie SE, Reilly MP. Heparin-induced thrombocytopenia and other immune thrombocytopenias: lessons from mouse models. Semin Thromb Hemostas. 2004;30:559–564
  72. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102(1):136–144
  73. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med. 2005;33(11):2540–2546
  74. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95(3):930–935
  75. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578–1584
  76. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Brit J Haematol. 2001;112(1):81–90
  77. Murphy WG, Moore JC, Barr RD, Pai MKR, Kelton JG. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. Brit J Haematol. 1987;66:509–514
  78. Fox JE. Shedding of adhesion receptors from the surface of activated platelets. Blood Coagulation Fibrinolysis. 1994;5(2):291–304
  79. Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet JM, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93(10):3451–3456
  80. Ogata N, Imaizumi M, Nomura S, Shozu A, Arichi M, Matsuoka M, et al. Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pract. 2005;68:193–201
  81. Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y, et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron. 1999;81(3):271
  82. Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia. 2002;45(4):550–555
  83. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 2002;106(19):2442–2447
  84. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost. 2006;4(3):566–573
  85. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003;145(6):962–970
  86. Bernal-Mizrachi L, Jy W, Fierro C, MacDonough R, Velazques HA, Purow J, et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol. 2004;97(3):439–446
  87. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26(1):112–116
  88. Simak J, Gelderman MP, Yu H, Wright V, Baird AE. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost. 2006;4(6):1296–1302
  89. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost. 2006;4(3):566–573
  90. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets. 2005;16(6):368–371
  91. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104(22):2649–2652
  92. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi-infarct dementias. Thromb Res. 1993;72(4):295–304
  93. Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006;168(3):1022–1030
  94. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585–1598
  95. Heresi GA, Chirinos JA, Velasquez H, Zambrano JP, Soriano AO, Horstman LL, et al. Elevated endothelial Microparticles (EMP) and activation markers of platelet and leukocytes in venous thromboembolism (VTE). Blood. 2003;102:804a
  96. Rectenwald JE, Myers DD, Hawley AE, Longo C, Henke PK, Guire KE, et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005;94(6):1312–1317
  97. Jy W, Horstman LL, Wang F, Duncan RC, Ahn YS. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res. 1995;80(6):471–482
  98. Steppich B, Mattisek C, Sobczyk D, Kastrati A, Schomig A, Ott I. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost. 2005;93(1):35–39
  99. Wakefield TW, Henke PK. The role of inflammation in early and late venous thrombosis: Are there clinical implications?. Semin Vasc Surg. 2005;18(3):118–129
  100. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006;52(4):657–664
  101. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med. 2005;37(1):61–66
  102. George JN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood. 1986;68:307–309
  103. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemostas. 2003;1(7):1637–1641
  104. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104(5):1534–1541

PII: S0268-960X(06)00052-X

doi: 10.1016/j.blre.2006.09.001

Blood Reviews
Volume 21, Issue 3 , Pages 157-171 , May 2007

Article Tools

* Image Usage & Resolution